Daily Cosmetic Research Analysis
Analyzed 12 papers and selected 3 impactful papers.
Summary
Three studies advance cosmetic and aesthetic surgery science from complementary angles: a validated cross-cultural inventory (RAABI) to quantify risky appearance-altering behaviors; a narrative systematic review linking cannabis use to higher hematoma, infection, and venous thromboembolism risks in breast reconstruction; and a propensity score–matched cohort showing single-port laparoscopy for benign ovarian cysts yields less pain, faster recovery, lower cost, and higher cosmetic satisfaction with comparable safety.
Research Themes
- Risk stratification in cosmetic and reconstructive surgery
- Patient-centered outcomes and cosmesis in minimally invasive gynecologic surgery
- Cross-cultural measurement of risky cosmetic behaviors
Selected Articles
1. The Risky Appearance Altering Behaviours Inventory (RAABI): A validated new outcome measure for sociocultural models of body image in English and Spanish speaking women.
RAABI was developed from culturally diverse focus groups and validated using EFA, CFA, ESEM, and bifactor ESEM among English- and Spanish-speaking women. It offers a standardized, cross-cultural measure of interest and engagement in risky cosmetic and appearance-altering behaviors, enabling robust tests of sociocultural body image models and surveillance of harmful practices.
Impact: This work fills a critical measurement gap by providing a validated, multilingual outcome measure for risky cosmetic behaviors, facilitating comparable research and targeted interventions across cultures.
Clinical Implications: Clinicians and public health programs can use RAABI to screen for high-risk cosmetic behavior patterns, guide counseling, and evaluate prevention strategies, particularly in populations vulnerable to harmful practices.
Key Findings
- RAABI captures interest and engagement in multiple risky appearance-altering behaviors, including surgical/non-surgical cosmetic procedures, diet pills, skin bleaching, and hair straightening.
- Items were generated via focus groups conducted across diverse cultural contexts to ensure content validity.
- Psychometric validation employed EFA, CFA, ESEM, and bifactor ESEM in English- and Spanish-speaking women, supporting its use as a cross-cultural outcome measure.
Methodological Strengths
- Multimethod psychometric evaluation (EFA, CFA, ESEM, bifactor ESEM)
- Content development grounded in cross-cultural focus groups and bilingual testing
Limitations
- Cross-sectional, self-report design limits causal inference and predictive validity.
- Generalizability to non-English/Spanish contexts and clinical settings requires further study; full sample details are not specified in the abstract.
Future Directions: Test measurement invariance across broader demographics, establish longitudinal predictive validity for adverse outcomes, and evaluate utility in clinical screening and intervention trials.
People worldwide use risky, potentially harmful cosmetic procedures to change their appearance. The newly developed Risky Appearance Altering Behaviours Inventory (RAABI) measures interest and engagement in appearance-altering behaviours, including surgical and non-surgical cosmetic procedures, diet pills, skin bleaching and hair straightening. RAABI items were constructed based on focus groups across diverse cultural contexts. Using exploratory factor analysis (EFA), confirmatory factor analysis (CFA), exploratory structural equation modelling (ESEM) and bifactor ESEM, we examined the psychometric properties of the RAABI among women from the UK (N = 784, M
2. Cannabis Use and Outcomes in Breast Surgery.
This narrative systematic review found that cannabis use may elevate hematoma, infection, and venous thromboembolism risks in implant-based and autologous breast reconstruction, while having no significant effect on breast reduction or cosmetic augmentation. Heterogeneity reflects small samples and nonstandardized definitions of cannabis exposure, underscoring the need for standardized assessments.
Impact: The review directly informs perioperative risk stratification and counseling for a growing patient population, highlighting procedure-specific risks linked to cannabis use in breast reconstruction.
Clinical Implications: Surgeons should screen for and document cannabis use, counsel patients about potential hematoma, infection, and VTE risks in reconstruction, and consider perioperative strategies (hemostasis vigilance, infection prevention, and VTE prophylaxis), especially with concomitant nicotine use.
Key Findings
- Across ten studies, cannabis use correlated with younger age and concomitant nicotine use among breast surgery patients.
- Cannabis use was linked to higher hematoma and wound-healing complications, increased thromboembolic events in autologous reconstruction, and increased infection risk in implant-based reconstruction.
- No significant impact of cannabis use was found for breast reduction and cosmetic breast augmentation.
- Heterogeneity stemmed from nonstandardized cannabis use definitions, small samples, and limited exposure characterization.
Methodological Strengths
- Comprehensive database search across PubMed, Embase, Web of Science, and Cochrane Library
- Procedure-specific synthesis across breast reduction, mastectomy, implant-based, and autologous reconstruction
Limitations
- Narrative synthesis with heterogeneity and lack of PRISMA-reported methodological rigor.
- Nonstandardized cannabis exposure definitions, small sample sizes, and retrospective designs limit inference.
Future Directions: Prospective studies using standardized, granular cannabis exposure metrics (dose, route, frequency, timing) and adjustment for confounders (e.g., nicotine) to refine perioperative protocols.
BACKGROUND: The rising prevalence of cannabis use introduces unique considerations for surgical patients, yet its impact in breast surgery remains poorly characterized. This narrative review synthesized available evidence investigating outcomes and postoperative complications associated with cannabis use across breast surgery, including breast reduction, mastectomy, implant-based breast surgery, and autologous breast reconstruction. METHODS: A systematic search of PubMed, Embase, Web of Science, and Cochrane Library identified studies reporting clinical outcomes of patients undergoing breast surgery with documented cannabis use. RESULTS: Among ten included studies, cannabis use was consistently associated with younger patient age and concomitant nicotine use. Across procedures, cannabis use was variably associated with increased risks of complications. The most salient findings included consistent reports of elevated hematoma risk and wound healing complications, thromboembolic events in autologous tissue breast reconstruction, and infection risk in implant-based breast reconstruction. However, findings were heterogeneous, largely attributable to variability in study design, most notably resulting from nonstandardized definitions of active cannabis use, small sample sizes, and the absence of detailed characterization of cannabis exposure. CONCLUSIONS: Cannabis use may increase perioperative risk in implant-based and autologous breast reconstruction, particularly for hematoma, infection, and venous thromboembolism. Cannabis use was not found to significantly impact outcomes in breast reduction and cosmetic breast augmentation. Evidence remains limited by nonstandardized reporting and a lack of prospective studies. Future research incorporating granular, standardized cannabis use assessments is needed to inform risk stratification and perioperative management of this growing patient population.
3. Comparative analysis of the efficacy of single-port
In a retrospective, propensity score–matched cohort of 260 patients with benign ovarian cysts, laparoendoscopic single-site surgery (LESS) achieved comparable safety and efficacy to multi-port laparoscopy, with lower 24-hour pain scores, milder inflammatory response, faster recovery, lower costs, and higher cosmetic satisfaction, while preserving ovarian reserve.
Impact: It adds patient-centered and cosmetic outcomes to the evidence base supporting LESS for benign ovarian cysts, informing surgical decision-making beyond traditional perioperative metrics.
Clinical Implications: For appropriate candidates, surgeons may offer LESS as a minimally invasive option prioritizing pain reduction, cosmetic satisfaction, and rapid recovery, contingent on surgical expertise and case selection.
Key Findings
- After propensity score matching, the LESS group had lower 24-hour VAS pain scores (2.36 ± 0.86).
- LESS demonstrated advantages of milder inflammation and faster recovery compared with multi-port laparoscopy.
- LESS was associated with lower costs and higher cosmetic satisfaction while preserving ovarian reserve.
- Overall safety and efficacy were comparable between LESS and multi-port laparoscopy for benign ovarian cysts.
Methodological Strengths
- Propensity score matching to reduce selection bias
- Comprehensive assessment of pain, inflammation, recovery time, cost, cosmetic satisfaction, and ovarian reserve
Limitations
- Retrospective, single-study design limits causal inference and external validity.
- Follow-up duration and some quantitative outcomes are not fully detailed in the abstract.
Future Directions: Prospective multicenter trials comparing LESS versus multi-port approaches with standardized outcome definitions and long-term reproductive and cosmetic outcomes.
OBJECTIVE: This study aimed to evaluate the efficacy, safety, and patient-centered outcomes of single-port laparoscopic surgery (LESS) METHODS: A retrospective cohort study enrolled 260 patients (January 2022-September 2025) divided into single-port group ( RESULTS: After PSM, the single-port group had lower 24-hour VAS scores (2.36 ± 0.86 CONCLUSION: LESS for benign ovarian cysts has comparable safety/efficacy to multi-port laparoscopy, with advantages of less pain, milder inflammation, faster recovery, lower costs, and better cosmetic satisfaction, while preserving ovarian reserve-making it a valuable minimally invasive option.